Hoth Therapeutics Unveils GDNF Breakthrough Data

March 5, 2025

DENVER, Colo., Mar 05, 2025 (247marketnews.com)- Hoth Therapeutics (NASDAQ:HOTH) unveiled preclinical findings that position Glial Cell Line-Derived Neurotrophic Factor (GDNF) as a potential treatment for obesity and related conditions like fatty liver disease. Conducted with the VA, this research could shift how we address one of the most pressing health issues.

The study, performed on GDNF-transgenic (GDNF-tg) mice, paints an extraordinary picture of GDNF’s capabilities. Unlike conventional obesity treatments that often rely on appetite suppression or carry a laundry list of side effects, GDNF tackles the problem at its metabolic roots. Key findings reveal that GDNF-tg mice, even on a high-fat diet, exhibited significantly lower body weight and reduced fat deposition. This was due to an enhanced basal metabolic rate, with increased oxygen consumption and carbon dioxide production driving higher energy expenditure.

Robb Knie CEO of Hoth, stated, “These compelling findings reinforce GDNF’s potential to fundamentally alter the way we approach obesity treatment. Unlike traditional weight-loss interventions that primarily focus on appetite suppression or caloric restriction, GDNF directly enhances the body’s natural ability to burn fat and increase metabolic efficiency.

“The data suggest that GDNF-based therapies could offer an entirely new approach to obesity treatment—one that activates the body’s natural metabolic processes to burn excess fat efficiently. This represents a significant advancement over current anti-obesity drugs, which often fail to maintain long-term weight loss.”

The implications are profound. GDNF appears to supercharge fat metabolism, promoting fat oxidation pathways while reducing adipogenesis—the formation of fat cells. By suppressing key fat-storage genes like PPAR-γ, FASN, and SREBF1, the body’s approach to handling excess calories is improved. GDNF-tg mice also improved insulin sensitivity, better glucose tolerance, and lower serum leptin levels—hallmarks of a healthier metabolic profile. Additionally, GDNF prevented hepatic steatosis, the fatty liver disease that often shadows obesity, which could also transform patient outcomes.

Obesity affects over 650 million adults worldwide, fueling deadly conditions including type 2 diabetes, cardiovascular disease, and metabolic syndrome. In the U.S., it contributes to $173 billion in annual healthcare costs, which underscores the urgent need for better solutions. Current pharmacological options often fall short, leaving patients grappling with limited results or intolerable side effects.

GDNF is focused on unlocking the body’s energy metabolism to enhance its natural ability to burn fat and maintain balance. For the millions struggling with obesity, this could mean a treatment that’s not only more effective but also more sustainable.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.